Novel targets for HIV therapy

Warner C. Greene; Zeger Debyser; Yasuhiro Ikeda; Eric O. Freed; Edward Stephens; Wes Yonemoto; Robert W. Buckheit; José A. Esté; Tomas Cihlar

doi:10.1016/j.antiviral.2008.08.003

Novel targets for HIV therapy

Warner C. Greene, Zeger Debyser, Yasuhiro Ikeda, Eric O. Freed, Edward Stephens, Wes Yonemoto, Robert W. Buckheit, José A. Esté, Tomas Cihlar

Molecular Medicine

Research output: Contribution to journal › Review article › peer-review

108 Scopus citations

Abstract

There are currently 25 drugs belonging to 6 different inhibitor classes approved for the treatment of human immunodeficiency virus (HIV) infection. However, new anti-HIV agents are still needed to confront the emergence of drug resistance and various adverse effects associated with long-term use of antiretroviral therapy. The 21st International Conference on Antiviral Research, held in April 2008 in Montreal, Canada, therefore featured a special session focused on novel targets for HIV therapy. The session included presentations by world-renowned experts in HIV virology and covered a diverse array of potential targets for the development of new classes of HIV therapies. This review contains concise summaries of discussed topics that included Vif-APOBEC3G, LEDGF/p75, TRIM 5α, virus assembly and maturation, and Vpu. The described viral and host factors represent some of the most noted examples of recent scientific breakthroughs that are opening unexplored avenues to novel anti-HIV target discovery and validation, and should feed the antiretroviral drug development pipeline in the near future.

Original language	English (US)
Pages (from-to)	251-265
Number of pages	15
Journal	Antiviral Research
Volume	80
Issue number	3
DOIs	https://doi.org/10.1016/j.antiviral.2008.08.003
State	Published - Dec 2008

Keywords

APOBEC3G
Human immunodeficiency virus
LEDGF/p75
Maturation
TRIM 5α
Vif
Virus assembly
Vpu

ASJC Scopus subject areas

Pharmacology
Virology

Access to Document

10.1016/j.antiviral.2008.08.003

Cite this

@article{f86ac68e34a1457fa82d4658df27a225,

title = "Novel targets for HIV therapy",

abstract = "There are currently 25 drugs belonging to 6 different inhibitor classes approved for the treatment of human immunodeficiency virus (HIV) infection. However, new anti-HIV agents are still needed to confront the emergence of drug resistance and various adverse effects associated with long-term use of antiretroviral therapy. The 21st International Conference on Antiviral Research, held in April 2008 in Montreal, Canada, therefore featured a special session focused on novel targets for HIV therapy. The session included presentations by world-renowned experts in HIV virology and covered a diverse array of potential targets for the development of new classes of HIV therapies. This review contains concise summaries of discussed topics that included Vif-APOBEC3G, LEDGF/p75, TRIM 5α, virus assembly and maturation, and Vpu. The described viral and host factors represent some of the most noted examples of recent scientific breakthroughs that are opening unexplored avenues to novel anti-HIV target discovery and validation, and should feed the antiretroviral drug development pipeline in the near future.",

keywords = "APOBEC3G, Human immunodeficiency virus, LEDGF/p75, Maturation, TRIM 5α, Vif, Virus assembly, Vpu",

author = "Greene, {Warner C.} and Zeger Debyser and Yasuhiro Ikeda and Freed, {Eric O.} and Edward Stephens and Wes Yonemoto and Buckheit, {Robert W.} and Est{\'e}, {Jos{\'e} A.} and Tomas Cihlar",

note = "Funding Information: The authors wish to thank Mike Bray for useful suggestions and comments and Gilead Sciences, Inc. for providing financial support to organize the ICAR 2008 Mini-Symposium on Novel HIV Targets.",

year = "2008",

month = dec,

doi = "10.1016/j.antiviral.2008.08.003",

language = "English (US)",

volume = "80",

pages = "251--265",

journal = "Antiviral Research",

issn = "0166-3542",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Novel targets for HIV therapy

AU - Greene, Warner C.

AU - Debyser, Zeger

AU - Ikeda, Yasuhiro

AU - Freed, Eric O.

AU - Stephens, Edward

AU - Yonemoto, Wes

AU - Buckheit, Robert W.

AU - Esté, José A.

AU - Cihlar, Tomas

N1 - Funding Information: The authors wish to thank Mike Bray for useful suggestions and comments and Gilead Sciences, Inc. for providing financial support to organize the ICAR 2008 Mini-Symposium on Novel HIV Targets.

PY - 2008/12

Y1 - 2008/12

N2 - There are currently 25 drugs belonging to 6 different inhibitor classes approved for the treatment of human immunodeficiency virus (HIV) infection. However, new anti-HIV agents are still needed to confront the emergence of drug resistance and various adverse effects associated with long-term use of antiretroviral therapy. The 21st International Conference on Antiviral Research, held in April 2008 in Montreal, Canada, therefore featured a special session focused on novel targets for HIV therapy. The session included presentations by world-renowned experts in HIV virology and covered a diverse array of potential targets for the development of new classes of HIV therapies. This review contains concise summaries of discussed topics that included Vif-APOBEC3G, LEDGF/p75, TRIM 5α, virus assembly and maturation, and Vpu. The described viral and host factors represent some of the most noted examples of recent scientific breakthroughs that are opening unexplored avenues to novel anti-HIV target discovery and validation, and should feed the antiretroviral drug development pipeline in the near future.

AB - There are currently 25 drugs belonging to 6 different inhibitor classes approved for the treatment of human immunodeficiency virus (HIV) infection. However, new anti-HIV agents are still needed to confront the emergence of drug resistance and various adverse effects associated with long-term use of antiretroviral therapy. The 21st International Conference on Antiviral Research, held in April 2008 in Montreal, Canada, therefore featured a special session focused on novel targets for HIV therapy. The session included presentations by world-renowned experts in HIV virology and covered a diverse array of potential targets for the development of new classes of HIV therapies. This review contains concise summaries of discussed topics that included Vif-APOBEC3G, LEDGF/p75, TRIM 5α, virus assembly and maturation, and Vpu. The described viral and host factors represent some of the most noted examples of recent scientific breakthroughs that are opening unexplored avenues to novel anti-HIV target discovery and validation, and should feed the antiretroviral drug development pipeline in the near future.

KW - APOBEC3G

KW - Human immunodeficiency virus

KW - LEDGF/p75

KW - Maturation

KW - TRIM 5α

KW - Vif

KW - Virus assembly

KW - Vpu

UR - http://www.scopus.com/inward/record.url?scp=56649085112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56649085112&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2008.08.003

DO - 10.1016/j.antiviral.2008.08.003

M3 - Review article

C2 - 18789977

AN - SCOPUS:56649085112

SN - 0166-3542

VL - 80

SP - 251

EP - 265

JO - Antiviral Research

JF - Antiviral Research

IS - 3

ER -

Novel targets for HIV therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this